DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dq24cc/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: South Korea" report to their offering.
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context.
The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
THE PHARMACEUTICAL MARKET: SOUTH KOREA - REVIEW
The implementation of the KORUS & EU-Korea Free-Trade Agreements (FTAs) will affect the South Korean pharmaceutical market. In November 2011, the KORUS FTA was approved, which is set to come into effect in January 2012. The KORUS FTA will include the phasing-out of tariffs for US drug companies and the introduction of a patent linkage system, whereby drug companies are unable to produce and sell generic drugs until the original patent expires. In July 2011, the EU-Korea FTA was implemented and it is expected to increase the volume and value of EU pharmaceuticals to South Korea due to an elimination of tariffs on EU exports.
In August 2011, the government and MOHW unveiled a set of plans to cut generic drug prices by up to a third, starting from 2012. These measures are expected to bring down the prices of some 8,776 registered drugs by around 17% on average. The MOHW has also decided to scrap the system whereby drug prices are graded in the order they were registered with the National Health Insurance system, in a bid to accelerate development of generic drugs as soon as the patents of the original drugs expire. Instead, payments for the same drugs will be capped irrespective of manufacturer to induce competition among pharmaceutical companies to develop better quality drugs.
The biologic sector in South Korea continues to witness rapid growth.
Key Topics Covered:
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
For more information visit http://www.researchandmarkets.com/research/dq24cc/the_pharmaceutical